☆ 4.3 Review

Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses-a systematic review

BMJ OPEN RESPIRATORY RESEARCH (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

Ronza Najjar-Debbiny et al.

Summary: This study assessed the effectiveness of Paxlovid in high-risk COVID-19 patients in real-world settings. The findings demonstrate that Paxlovid is highly effective in reducing the risk of death and severe COVID-19 in the Omicron era. The study also suggests that Paxlovid may be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease. Vaccination status did not significantly impact the effectiveness of Paxlovid.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Emerging aspects of cytokine storm in COVID-19: The role of proinflammatory cytokines and therapeutic prospects

Renu Dharra et al.

Summary: Since the initial cases were reported in Wuhan, China, in 2019, COVID-19 has caused millions of deaths during the last 3 years. Patients with COVID-19 experience severe pneumonia, high fever, acute respiratory distress syndrome (ARDS), and multiple-organ dysfunction, which can be fatal. Cytokine storm (CS) is a hyperactivation of the immune system, leading to excessive immune cell infiltrations in the lungs and other organs, causing tissue damage. Controlling the CS is crucial in treating COVID-19, and various strategies such as monoclonal antibodies, combination therapies, and stem cell therapy are employed.

CYTOKINE (2023)

添加到收藏夹

Review Medicine, General & Internal

Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis

Karima Benaicha et al.

Summary: The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or moderate COVID-19 patients. The meta-analysis included 10 studies and concluded that molnupiravir has a significant impact on reducing all-cause mortality and improving the proportion of patients who test negative for viral RNA on day five. The subgroup analysis showed consistent results across all subgroups, indicating that the effect of molnupiravir is consistent regardless of patient characteristics.

CUREUS JOURNAL OF MEDICAL SCIENCE (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome

Maria Candida Cesta et al.

Summary: This review highlights the role of interleukin 8 (IL-8) in modulating the hyperinflammatory response in acute respiratory distress syndrome (ARDS), suggesting IL-8 as a possible new therapeutic target.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Circulating LIGHT (TNFSF14) and Interleukin-18 Levels in Sepsis-Induced Multi-Organ Injuries

Hui-Qi Qu et al.

Summary: This study investigates the associations of cytokines LIGHT and IL-18 with ARDS, AHRF, or AKI caused by non-COVID-19 viral or bacterial sepsis. The results show increased levels of LIGHT in bacterial sepsis and sepsis from viral infections, while IL-18 levels vary greatly and are consistently associated with severity scores, mortality, and AKI.

BIOMEDICINES (2022)

添加到收藏夹

Article Critical Care Medicine

Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19 A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial

Christopher D. Barrett et al.

Summary: This study investigated the effects of tissue plasminogen activator (tPA) on pulmonary function in severe COVID-19 respiratory failure. The results showed significant improvement in lung oxygenation in the tPA bolus group compared to the control group. However, there were no statistically significant differences in the improvement of PaO2/FIO2 ratio, composite outcome, ventilator-free days, and in-hospital mortality between the tPA bolus group and the control group.

CHEST (2022)

添加到收藏夹

Review Infectious Diseases

Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis

Todd C. Lee et al.

Summary: Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Respiratory System

RAND appropriateness panel to determine the applicability of UK guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemic

Mark Griffiths et al.

Summary: COVID-19 has become a common cause of ARDS worldwide, with pathophysiological and clinical features that distinguish it from traditional ARDS. An expert panel recommended adherence to evidence-based supportive strategies for managing ARDS, regardless of the presence or absence of COVID-19. For patients with ARDS and COVID-19, routine corticosteroid treatment and a lower threshold for full anticoagulation are recommended based on suspicion for venous thromboembolic disease.

THORAX (2022)

添加到收藏夹

Review Oncology

A narrative review of COVID-19-related acute respiratory distress syndrome (CARDS): typical or atypical ARDS?

Dan Pu et al.

Summary: COVID-19-related ARDS (CARDS) has some differences compared to classic ARDS in terms of disease onset, hypoxemia, and thrombogenic processes. Despite these differences, clinicians should continue to follow the treatment framework for ARDS when managing CARDS patients.

ANNALS OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Review Biology

Acute Respiratory Distress Syndrome and the Use of Inhaled Pulmonary Vasodilators in the COVID-19 Era: A Narrative Review

Adeel Nasrullah et al.

Summary: COVID-19 pandemic has caused significant morbidity and mortality, especially from severe acute respiratory distress syndrome (ARDS). The management of COVID-19-associated ARDS (CARDS) involves lung-protective ventilation, prone ventilation, neuromuscular blockade, and possibly a trial of pulmonary vasodilators for refractory hypoxemia.

LIFE-BASEL (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome

David S. Perlin et al.

Summary: This study demonstrates that the use of CERC-002 treatment in patients with COVID-19-associated ARDS can reduce LIGHT levels and may decrease the risk of respiratory failure and death.

JOURNAL OF CLINICAL INVESTIGATION (2022)

添加到收藏夹

Correction Critical Care Medicine

Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS (July, 10.1007/s00134-020-06192-2, 2020)

Carlos Ferrando et al.

Summary: Mistakes were found in Figures 1 and 3 in the original version of the article.

INTENSIVE CARE MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019

Kathryn W. Hendrickson et al.

CRITICAL CARE CLINICS (2021)

添加到收藏夹

Review Medicine, General & Internal

Severe covid-19 pneumonia: pathogenesis and clinical management

Amy H. Attaway et al.

Summary: Severe covid-19 pneumonia presents challenges for medical research and treatment, with specific risk factors and clinical features identified. Approaches involving high flow nasal cannula, ventilation strategies, and medication choices are important for managing severe cases. Comprehensive interdisciplinary methods are essential for the recovery of critically ill covid-19 patients.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Review Cell & Tissue Engineering

Stem cell-based therapy for COVID-19 and ARDS: a systematic review

Gabriele Zanirati et al.

Summary: This study conducted a systematic review of 30 clinical studies on COVID-19 and ARDS treatment, with most studies utilizing MSCs for treatment. Findings suggest a positive impact of stem cell therapy on immunological and inflammatory processes in COVID-19 and ARDS patients, with no reported deaths causally linked to cell therapy. The results support the consideration of MSCs treatment as a potential candidate for adjuvant therapy in moderate-to-severe COVID-19 cases and compassionate use.

NPJ REGENERATIVE MEDICINE (2021)

添加到收藏夹

Review Respiratory System

Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management

Anolin Aslan et al.

Summary: The COVID-19 pandemic is a serious issue in the new era, with a focus on controlling lung diseases such as ARDS and lung failure. Ongoing research is crucial, with current emphasis on managing COVID-19 patients and evaluating treatment strategies for ARDS induced by COVID-19.

PNEUMONIA (2021)

添加到收藏夹

Article Infectious Diseases

Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019

Alanna C. McEneny-King et al.

Summary: The evaluation of 22 patients with severe COVID-19 showed that the modified dosing regimen of ravulizumab effectively reduced complement activation, supporting its continued use in the ongoing phase 3 study.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Article Cell Biology

SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target

Bingqing Xia et al.

Summary: The study demonstrated that the SARS-CoV-2 protein 2-E alone can cause acute respiratory distress syndrome (ARDS)-like damage and induce rapid cell death and cytokine release. Inhibiting the 2-E channel can effectively reduce the viral load and secretion of inflammation cytokines in the lungs, making it a promising drug target against SARS-CoV-2.

CELL RESEARCH (2021)

添加到收藏夹

Article Medicine, General & Internal

Comparative Study of Acute Lung Injury in COVID-19 and Non-COVID-19 Patients

Jianguo Zhang et al.

Summary: Comparing the characteristics of ALI between COVID-19 and non-COVID-19 patients in the ICU setting provided insights into the pathogenesis of ALI induced by different risk factors, suggesting distinct treatment plans.

FRONTIERS IN MEDICINE (2021)

添加到收藏夹

Article Infectious Diseases

Neutrophils and secondary infections in COVID-19 induced acute respiratory distress syndrome

Z. M. Holliday et al.

Summary: SARS-CoV-2 virus is responsible for the global pandemic, affecting over 188 countries. Patients with severe respiratory disease caused by SARS-CoV-2 are at risk for secondary infections, and elevated levels of neutrophils in bronchoalveolar fluid and C-reactive protein in serum may be correlated with secondary infections.

NEW MICROBES AND NEW INFECTIONS (2021)

添加到收藏夹

Article Respiratory System

COVID-19 versus Non-COVID-19 Acute Respiratory Distress Syndrome Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical Outcomes

William Bain et al.

Summary: COVID-19 ARDS and ARDS from other etiologies have differences in demographic, physiologic parameters, and clinical outcomes, such as IL-6 levels and minute ventilation. Despite some similarities, COVID-19 ARDS shows longer duration of mechanical ventilation compared to other ARDS patients.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2021)

添加到收藏夹

Letter Critical Care Medicine

Respiratory Mechanics of COVID-19-versus Non-COVID-19-associated Acute Respiratory Distress Syndrome

Anne-Fleur Haudebourg et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

添加到收藏夹

Review Critical Care Medicine

Evidence-Based Practices for Acute Respiratory Failure and Acute Respiratory Distress Syndrome A Systematic Review of Reviews

Jennifer N. Ervin et al.

CHEST (2020)

添加到收藏夹

Review Medicine, Research & Experimental

The complement system in COVID-19: friend and foe?

Anuja Java et al.

JCI INSIGHT (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19ARDS

Peter G. Gibson et al.

MEDICAL JOURNAL OF AUSTRALIA (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease

Chih-Chao Chiang et al.

FRONTIERS IN PHARMACOLOGY (2020)

添加到收藏夹

Review Immunology

GM-CSF: A Promising Target in Inflammation and Autoimmunity

Kevin M. C. Lee et al.

IMMUNOTARGETS AND THERAPY (2020)

添加到收藏夹

Letter Peripheral Vascular Disease

Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension

Erkan Cure et al.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2020)

添加到收藏夹

Review Critical Care Medicine

Carbon monoxide in intensive care medicine-time to start the therapeutic application?!

Ulrich Goebel et al.

INTENSIVE CARE MEDICINE EXPERIMENTAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Acute respiratory distress syndrome

Michael A. Matthay et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

添加到收藏夹

Article Critical Care Medicine

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Michael A. Matthay et al.

LANCET RESPIRATORY MEDICINE (2019)

添加到收藏夹

Article Critical Care Medicine

Complications and Outcomes of Acute Respiratory Distress Syndrome

Briana DiSilvio et al.

CRITICAL CARE NURSING QUARTERLY (2019)

添加到收藏夹

Review Medicine, General & Internal

Pharmacological agents for adults with acute respiratory distress syndrome

Sharon R. Lewis et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)

添加到收藏夹

Review Medicine, General & Internal

Acute Respiratory Distress Syndrome

B. Taylor Thompson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Critical Care Medicine

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Akram Khan et al.

CRITICAL CARE (2017)

添加到收藏夹

Letter Respiratory System

Incidence and recognition of acute respiratory distress syndrome in a UK intensive care unit

Charlotte Summers et al.

THORAX (2016)

添加到收藏夹

Editorial Material Critical Care Medicine

Future therapies for ARDS

Gerard F. Curley et al.

INTENSIVE CARE MEDICINE (2015)

添加到收藏夹

Article Emergency Medicine

Albuterol in the treatment of acute respiratory distress syndrome: A meta-analysis of randomized controlled trials

Ruo Wu et al.

WORLD JOURNAL OF EMERGENCY MEDICINE (2015)

添加到收藏夹

Review Respiratory System

The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections

SeungHye Han et al.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2015)

添加到收藏夹

Review Physiology

The mercurial nature of neutrophils: still an enigma in ARDS?

Andrew E. Williams et al.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2014)

添加到收藏夹

Article Critical Care Medicine

The Beta Agonist Lung Injury Trial Prevention

Gavin D. Perkins et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)

添加到收藏夹

Article Computer Science, Information Systems

A Systems-of-Systems Perspective on Healthcare: Insights From Two Multi-Method Exploratory Cases of Leading US and UK Hospitals

Jorge M. S. Fradinho et al.

IEEE SYSTEMS JOURNAL (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Biological properties of adrenomedullin conjugated with polyethylene glycol

Keishi Kubo et al.

PEPTIDES (2014)

添加到收藏夹

Review Medicine, General & Internal

Ventilator-Induced Lung Injury

Arthur S. Slutsky et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial

Fang Gao Smith et al.

LANCET (2012)

添加到收藏夹

Article Public, Environmental & Occupational Health

Recombinant Angiotensin-Converting Enzyme 2 Suppresses Pulmonary Vasoconstriction in Acute Hypoxia

Axel Kleinsasser et al.

WILDERNESS & ENVIRONMENTAL MEDICINE (2012)

添加到收藏夹

Article Critical Care Medicine

Randomized, Placebo-controlled Clinical Trial of an Aerosolized β2-Agonist for Treatment of Acute Lung Injury

Michael A. Matthay et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome

Sara C. Sebag et al.

CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)

添加到收藏夹

Article Critical Care Medicine

Approaches to Refractory Hypoxemia in Acute Respiratory Distress Syndrome: Current Understanding, Evidence, and Debate

Stephen R. Collins et al.

RESPIRATORY CARE (2011)

添加到收藏夹

Article Medicine, General & Internal

Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome.

Laurent Papazian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Psychiatry

Psychiatric morbidity in survivors of the acute respiratory distress syndrome: A systematic review

Dimitry S. Davydow et al.

PSYCHOSOMATIC MEDICINE (2008)

添加到收藏夹

Review Biochemistry & Molecular Biology

Acute lung injury and the acute respiratory distress syndrome - Four decades of inquiry into pathogenesis and rational management

MA Matthay et al.

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2005)

添加到收藏夹

Article Medicine, General & Internal

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome

TWK Lew et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.